Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | CCR5 | P51681 | 1/20 | 0.57 |
| ▸ | CCR8 | P51685 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623765 | 0.78 | KDM4E (0.53) | CCR1CCR5CCR8METAP2KDM4E | |
| SCHEMBL29397106 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL181893 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL31482991 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL6820765 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL2258309 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL15664136 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| Hydrochloric Acid SCHEMBL5549447 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL32670845 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 | |
| Hydrochloric Acid SCHEMBL9639295 | 0.73 | CCR1 (0.94) | CCR1CCR5CCR8METAP2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1471055-A1 | 6-phenylpyridyl-2-amine derivatives | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0819135-B1 | SUGAR-MODIFIED CYTOSTATICS | BAYER AG (DE) | 1999-11-17 | — | — | EP | disclosed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | CCR1 4234/4885CCR5 2888/4885CCR8 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.